Wednesday, February 22, 2017| Blindness, Dry Eye, Eyegate Pharmaceuticals, Inflammation, Shire, Valeant

EyewireTV — Early Xiidra Sales; Valeant Boosts Ophthalmic Portfolio

In this week’s EyewireTV, Shire releases information about the early sales of its dry eye disease drug Xiidra (lifitegrast); and Valeant acquires the global commercial and manufacturing rights to EyeGate Pharmaceuticals’ EyeGate II Delivery System and EGP-437 combination product for postoperative pain and inflammation. Also, the Himalayan Cataract Project, a major eye care initiative to develop sustainable solutions for blindness throughout Asia and Africa, is one of eight finalists in a $100 million global competition.

Watch Video

Wednesday, February 15, 2017| FDA Approval/Clearance, Lions Eye Institute, Lucentis

EyewireTV — Lucentis Launches Prefilled Syringe; LEITR Doubles in Size

In this week’s EyewireTV, Lucentis (ranibizumab) is now available in the United States in a new 0.5-mg prefilled syringe; and the Lions Eye Institute for Transplant & Research has doubled its size after acquiring International Sight Restoration, the largest eye bank for international ocular distribution. Also, three companies with early-stage products for serious ocular conditions (Aura Biosciences, Regenxbio, and GenSight Biologics) receive the green light from the FDA to proceed with clinical development.

Watch Video

Wednesday, February 08, 2017| Glaucoma

EyewireTV — World’s Top Glaucoma Specialists Discuss Future Treatment Options

In this week’s EyewireTV, leading glaucoma specialists, investors, and industry executives gather at the Glaucoma 360 meeting in San Francisco to exchange ideas and provide updates on new developments in glaucoma. Several attendees talk to EyewireTV about which technologies or treatment options—either already available or in clinical development—they believe will have a major impact on the way glaucoma patients are treated.

Watch Video

Wednesday, February 01, 2017| Alcon, Astigmatism, LENSAR Laser, Novartis, Retinal Vein Occlusion, RVO

EyewireTV — Novartis Considers Alcon Spinoff; Robot Used for RVO Surgery

In this week’s EyewireTV, Novartis executives say they are considering several options for the company's Alcon unit, including the possibility of separating from the eye care division; and Lensar announces the launch of Streamline III, an upgrade to the Lensar laser system that facilitates more precise and intuitive astigmatism management. Also, surgeons in Belgium for the first time use robotic support to safely dissolve a blood clot in a patient with retinal vein occlusion.

Watch Video

Wednesday, January 25, 2017| Dry Eye, FDA Approval/Clearance, Implantable Miniature Telescope, IMT, Intraocular lens, IOL, IOLs, Macular Degeneration, VisionCare Ophthalmic Technologies

EyewireTV — New Dextenza NDA; Dry Eye Projections

In this week’s EyewireTV, 6 months after being turned down by the FDA, Ocular Therapeutix resubmits a new drug application for Dextenza (dexamethasone insert 0.4 mg) for the treatment of ocular pain after ophthalmic surgery; and the FDA grants VisionCare approval to initiate a clinical study of its miniature telescope implant in patients with end-stage macular degeneration who were previously implanted with an IOL. Also, a new report form Market Scope projects the global dry eye treatments market to grow significantly over the next 5 years—driven by new drugs and procedures, along with better access.

Watch Video

Wednesday, January 18, 2017| Cataract, Drug Delivery, Essilor, ForSight Vision, Glaucoma, Imprimis Pharmaceuticals, Luxottica Group, Roche

EyewireTV - Blockbuster Eyewear Merger; New Imprimis Formulations

In this week’s EyewireTV, Luxottica Group, the Italian maker of Ray-Ban sunglasses, agrees to a merger with French optical lens maker Essilor International, creating a $49 billion eyewear giant; and Imprimis Pharmaceuticals introduces several new cataract and glaucoma formulations. Also, Roche acquires ForSight Vision4, providing Roche exclusive access to a proprietary eye drug delivery technology.

Watch Video

Wednesday, January 11, 2017| Abbott Medical Optics, AMO, Astigmatism, Choroidal Neovascularization, CNV, Clinical Trials, Dry Eye, Excimer Lasers, FDA Approval/Clearance, LASIK, Lucentis, Sun Pharma

EyewireTV - New Lucentis Indication; LASIK for Mixed Astigmatism

In this week’s EyewireTV, the FDA approves Lucentis (ranibizumab 0.5 mg) for the treatment of myopic choroidal neovascularization; and Sun Pharma announces successful phase 3 confirmatory clinical trial results for its dry eye disease treatment candidate Seciera (cyclosporine A 0.09%). Also, the FDA approves Abbott’s Star S4 IR excimer laser system and iDesign Advanced WaveScan Studio System for use in LASIK patients with mixed astigmatism.

Watch Video

Wednesday, January 04, 2017| Acquisitions, Mergers, AcrySof® IQ ReSTOR Multifocal IOL, Alcon, Cataract Surgery, Clinical Trials, Corneal Astigmatism, FDA Approval/Clearance, Glaucoma, Inotek Pharmaceuticals, Multifocal IOLs, Novartis, Presbyopia, Toric IOLs

EyewireTV - ReSTOR +3.0 Approved; Novartis Acquires Maker of Presbyopia Eye Drop

In this week’s EyewireTV, Alcon receives FDA approval for the AcrySof IQ ReSTOR +3.0D multifocal toric IOL, which is designed to address presbyopia and preexisting corneal astigmatism at the time of cataract surgery; and Inotek Pharmaceuticals’s glaucoma treatment candidate trabodenoson fails to meet its primary endpoint in a phase 3 trial. Also, Novartis enters into a definitive agreement to acquire privately held Encore Vision, which is developing a topical treatment for presbyopia.

Watch Video

Wednesday, December 28, 2016| Acquisitions, Mergers, Cornea, Corneal Collagen Crosslinking, CXL, Dry Eye, FDA Approval/Clearance, Microinvasive Glaucoma Surgery (MIGS), Myopia

EyewireTV - 2016 Year in Review

In this week’s EyewireTV, we take a look back at the major industry announcements and advancements in ophthalmology in 2016. The top stories included the first FDA approval of a dry eye drug in the United States in more than a decade; the US commercialization of corneal collagen cross-linking; the approval and launch of an entirely new option in the surgical treatment of myopia; the approval of an implantable device that changes the shape of the cornea; the release of new postoperative drop formulations; and the advancement of MIGS devices. The year also featured a major merger in ophthalmology, and another blockbuster merger that was called off.

Watch Video

Wednesday, December 21, 2016| Business, Glaucoma, Glaukos Corporation, Intraocular Pressure, IOP, iStent, LENSAR Laser, Microinvasive Glaucoma Surgery (MIGS)

EyewireTV - Glaucoma Projections; Experts' Clinical Trial Advice

In this week’s EWTV, a new report projects the number of people affected by glaucoma in the United States will increase nearly 50 percent in the next 15 years; and an international study shows that Glaukos’ iStent inject next-generation MIGS device was successful in lowering IOP in a standalone procedure. Also, Lensar, maker of the Lensar femtosecond laser system, files for Chapter 11 bankruptcy in an effort to reduce debt and strengthen its balance sheet.

Watch Video

Wednesday, December 14, 2016| Clinical Trials, genetic testing, Glaucoma, Ophthotech, Ranibizumab, Spark Therapeutics

EyewireTV — Late-Stage Wet AMD Drug Fails; Glaucoma Linked to Zika

In this week’s EyewireTV, Ophthotech is dealt a major setback as its product candidate Fovista (pegpleranib) combined with monthly Lucentis (ranibizumab) fails to show significant benefit over anti-VEGF monotherapy in two phase 3 trials; and new research demonstrates for the first time that the Zika virus can cause glaucoma in infants who were exposed to the virus during pregnancy. Also, Spark Therapeutics launches an initiative aimed at improving access to genetic testing for inherited retinal diseases.

Watch Video

Wednesday, December 07, 2016| Diabetic Retinopathy, FDA Approval/Clearance, Glaucoma, Heidelberg Engineering, Microinvasive Glaucoma Surgery (MIGS), Optical Coherence Tomography Angiography, OCTA, XEN

EyewireTV - Google AI for Diabetic Retinopathy; Early XEN Feedback

In this week's EyewireTV, Google researchers are working with doctors to develop an artificial intelligence that can automatically identify diabetic retinopathy; and Heidelberg Engineering starts delivering its OCT-Angiography Module to Spectralis customers outside the United States. In the feature, three ophthalmologists who were among the first to perform surgery with the XEN Glaucoma Treatment System since it received FDA clearance discuss their experience with the new MIGS procedure.

Watch Video

Wednesday, November 30, 2016| Cataract Surgery, Inflammation, Laser photocoagulation, LASIK, Sun Pharma

EyewireTV - New FDA LASIK Data Revealed; BromSite Launched in US

In this week’s EyewireTV, a major government-sponsored study finds that the vast majority of LASIK patients are happy with their vision after surgery; however, a subset of patients experience new visual symptoms and Sun Pharma announces the US launch of BromSite (bromfenac ophthalmic solution) for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. Also, OD-OS announces FDA 510(k) clearance of the Navilas 577s laser photocoagulator.

Watch Video

Tuesday, November 22, 2016| Allergan, Carl Zeiss Meditec, Clinical Trials, FDA Approval/Clearance, Glaucoma, Omidria, optical coherence tomography angiography, OCT angiography, Pediatric, PLEX Elite 9000, XEN

EyewireTV — XEN Glaucoma System Cleared by FDA; New OCT Angiography Platform

In this week’s EyewireTV, Allergan receives FDA clearance of the XEN Glaucoma Treatment System; and Carl Zeiss Meditec receives FDA clearance of the Zeiss PLEX Elite 9000, a swept-source OCT and OCT angiography platform. Also, in a post-marketing clinical trial, Omidria was shown to be safe and well tolerated in children undergoing cataract surgery.

Watch Video

Wednesday, November 16, 2016

EyewireTV - Novartis Considers Sale of Alcon; Dextenza Phase 3 Results

In this week’s EyewireTV, Novartis executives say they are considering a sale of the Alcon division; and Ocular Therapeutix announces positive topline results from its phase 3 clinical trial of Dextenza (dexamethasone insert 0.4 mg) for the treatment of postsurgical ocular inflammation and pain. Also, Pixium Vision announces the successful implantation and activation of its IRIS II bionic vision system in the UK.

Watch Video
Load More